Akumin Inc. (AKU)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Akumin Inc. (AKU) with AI Score 53/100 (Hold). Akumin Inc. is a leading provider of outpatient diagnostic imaging services in the United States, operating through a network of approximately 200 owned and/or operated imaging locations. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Akumin Inc. (AKU) Healthcare & Pipeline Overview
Akumin Inc. delivers outpatient diagnostic imaging services in the U.S., offering radiology and oncology solutions to hospitals and health systems. With a network of 200 locations, the company provides MRI, CT, and other imaging modalities. Despite negative profitability, Akumin plays a crucial role in healthcare diagnostics.
Investment Thesis
Akumin Inc. presents a complex investment case. While the company plays a vital role in providing outpatient diagnostic imaging services, its financial performance raises concerns. With a market capitalization of $0.03 billion and a negative P/E ratio of -0.17, the company's profitability is a significant challenge, further highlighted by a negative profit margin of -20.2%. The company's gross margin stands at 18.8%. Potential growth catalysts include expanding its network of imaging locations and increasing service offerings. However, the company must address its profitability issues to ensure long-term sustainability. Investors should closely monitor Akumin's ability to improve its financial performance and capitalize on growth opportunities in the diagnostic imaging market.
Based on FMP financials and quantitative analysis
Key Highlights
- Akumin operates approximately 200 owned and/or operated imaging locations across the United States.
- The company provides services to approximately 1,000 hospitals and health systems in 46 states.
- Akumin's market capitalization is $0.03 billion, reflecting its current market valuation.
- The company's P/E ratio is -0.17, indicating negative earnings.
- Akumin's profit margin is -20.2%, highlighting profitability challenges.
Competitors & Peers
Strengths
- Extensive network of imaging centers.
- Established relationships with hospitals and health systems.
- Comprehensive range of diagnostic imaging services.
- Presence in multiple states across the United States.
Weaknesses
- Negative profit margin.
- High debt levels.
- Dependence on reimbursement rates.
- Competition from larger imaging providers.
Catalysts
- Ongoing: Expansion of imaging center network through acquisitions and new site development.
- Ongoing: Implementation of new technologies to improve diagnostic accuracy and efficiency.
- Upcoming: Potential partnerships with healthcare providers to expand referral network.
- Upcoming: Focus on oncology services to capitalize on growing demand for cancer diagnostics and treatment.
Risks
- Ongoing: Changes in reimbursement policies affecting revenue and profitability.
- Ongoing: Increased competition from other imaging providers.
- Potential: Economic downturn affecting healthcare spending.
- Potential: Technological obsolescence requiring significant capital investment.
- Potential: Integration risks associated with acquisitions.
Growth Opportunities
- Expansion of Service Offerings: Akumin can expand its service offerings to include more specialized diagnostic procedures and interventional radiology services. This would allow the company to attract a broader range of patients and increase revenue per location. The market for specialized diagnostic services is growing, driven by advancements in medical technology and increasing demand for personalized medicine. Timeline: 1-2 years. Market Size: $10 billion annually.
- Strategic Acquisitions: Akumin can pursue strategic acquisitions of smaller imaging centers and radiology practices to expand its geographic footprint and market share. This would allow the company to enter new markets and consolidate its position in existing markets. The market for imaging center acquisitions is active, with numerous opportunities available. Timeline: Ongoing. Market Size: $5 billion annually.
- Technological Upgrades: Investing in advanced imaging technologies, such as AI-powered diagnostic tools and high-resolution imaging systems, can improve the accuracy and efficiency of Akumin's services. This would allow the company to attract more patients and improve patient outcomes. The market for advanced imaging technologies is growing rapidly. Timeline: 1-3 years. Market Size: $3 billion annually.
- Partnerships with Healthcare Providers: Akumin can form strategic partnerships with hospitals, physician groups, and other healthcare providers to expand its referral network and increase patient volume. This would allow the company to access a larger pool of patients and integrate its services into the broader healthcare ecosystem. Timeline: Ongoing. Market Size: $2 billion annually.
- Focus on Oncology Services: Akumin can focus on expanding its oncology services, such as PET/CT imaging and radiation therapy, to capitalize on the growing demand for cancer diagnostics and treatment. This would allow the company to tap into a high-growth market segment and improve its profitability. The market for oncology services is growing rapidly. Timeline: 2-3 years. Market Size: $7 billion annually.
Opportunities
- Expansion into new geographic markets.
- Increased demand for outpatient imaging services.
- Technological advancements in diagnostic imaging.
- Partnerships with healthcare providers and payers.
Threats
- Changes in reimbursement policies.
- Increased competition from other imaging providers.
- Economic downturn affecting healthcare spending.
- Technological obsolescence.
Competitive Advantages
- Extensive network of approximately 200 imaging locations.
- Relationships with approximately 1,000 hospitals and health systems.
- Comprehensive suite of diagnostic imaging services.
- Established presence in 46 states across the United States.
About AKU
Akumin Inc., founded in 2015 and headquartered in Plantation, Florida, is a prominent provider of outpatient diagnostic imaging services in the United States. The company operates through two primary segments: Radiology and Oncology. Akumin offers a comprehensive suite of medical imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and various other diagnostic and interventional radiology procedures. These services are delivered through a network of approximately 200 owned and/or operated imaging locations. Akumin's services cater to a broad spectrum of healthcare needs, supporting the diagnostic and treatment pathways for numerous medical conditions. The company partners with approximately 1,000 hospitals and health systems across 46 states, providing them with outpatient radiology and oncology services and solutions. This extensive network allows Akumin to reach a significant patient population and contribute to the efficiency and effectiveness of healthcare delivery. The company's focus on outpatient services aims to provide convenient and cost-effective access to essential diagnostic imaging, reducing the burden on hospital resources and improving patient outcomes. Akumin's commitment to innovation and quality in diagnostic imaging has positioned it as a key player in the evolving healthcare landscape.
What They Do
- Provides outpatient diagnostic imaging services.
- Offers magnetic resonance imaging (MRI) services.
- Performs computed tomography (CT) scans.
- Conducts positron emission tomography (PET) scans.
- Offers nuclear medicine services.
- Provides mammography and ultrasound services.
- Delivers digital radiography and fluoroscopy procedures.
- Offers interventional radiology procedures.
Business Model
- Generates revenue by providing diagnostic imaging services to patients.
- Contracts with hospitals and health systems to provide outpatient radiology and oncology solutions.
- Operates a network of owned and/or operated imaging locations.
- Focuses on outpatient services to provide convenient and cost-effective access to diagnostic imaging.
Industry Context
The medical diagnostics and research industry is experiencing growth driven by technological advancements, an aging population, and increasing prevalence of chronic diseases. Companies like Akumin play a crucial role in providing essential diagnostic imaging services. The industry is competitive, with players like ABDXF (Abdos Healthcare), AWH (American WholeHealth), CNTG (Centogene), DMTKQ (DMC Global Inc.), and LMDX (Lantheus Holdings) vying for market share. Market trends include a shift towards outpatient services, increasing demand for advanced imaging modalities, and the integration of AI and machine learning to improve diagnostic accuracy and efficiency.
Key Customers
- Hospitals and health systems across the United States.
- Physician groups and medical practices.
- Patients requiring diagnostic imaging services.
- Oncology centers and cancer treatment facilities.
Financials
Chart & Info
Akumin Inc. (AKU) stock price: Price data unavailable
Latest News
-
Akumin Announces Changes To Leadership Team; Krishna Kumar, Current President & Chief Operating Officer, Appointed Chief Executive Officer
benzinga · Feb 8, 2024
-
Crude Oil Falls Sharply; Apollomics Shares Plunge
benzinga · Oct 23, 2023
-
Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
benzinga · Oct 23, 2023
-
Nasdaq Turns Higher; Akumin Shares Jump
benzinga · Oct 23, 2023
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AKU.
Price Targets
Wall Street price target analysis for AKU.
MoonshotScore
What does this score mean?
The MoonshotScore rates AKU's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Akumin Announces Changes To Leadership Team; Krishna Kumar, Current President & Chief Operating Officer, Appointed Chief Executive Officer
Crude Oil Falls Sharply; Apollomics Shares Plunge
Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Nasdaq Turns Higher; Akumin Shares Jump
Leadership: Riadh Zine-El-Abidine
CEO
Riadh Zine-El-Abidine is the Chief Executive Officer of Akumin Inc. He has extensive experience in the healthcare industry, with a focus on diagnostic imaging and healthcare management. His career includes leadership roles in various healthcare organizations, where he has been responsible for strategic planning, operational management, and business development. He is known for his expertise in driving growth and improving operational efficiency. His leadership is focused on expanding Akumin's market presence and enhancing its service offerings.
Track Record: Under Riadh Zine-El-Abidine's leadership, Akumin Inc. has focused on expanding its network of imaging centers and strengthening its relationships with hospitals and health systems. He has overseen the implementation of new technologies and services to improve patient care and operational efficiency. Key milestones include strategic acquisitions and partnerships aimed at increasing market share and enhancing the company's competitive position. His focus remains on improving financial performance and driving sustainable growth.
Akumin Inc. Stock: Key Questions Answered
What does Akumin Inc. do?
Akumin Inc. is a leading provider of outpatient diagnostic imaging services in the United States. The company operates a network of approximately 200 owned and/or operated imaging locations, offering a comprehensive range of services, including MRI, CT, PET, and other diagnostic procedures. Akumin partners with hospitals, health systems, and physician groups to provide convenient and cost-effective access to high-quality imaging services, supporting the diagnostic and treatment pathways for various medical conditions.
What do analysts say about AKU stock?
Analyst coverage of Akumin Inc. is currently limited. Key valuation metrics, such as the P/E ratio, reflect the company's current financial challenges. Growth considerations include the company's ability to expand its network, improve operational efficiency, and capitalize on the growing demand for outpatient imaging services. Investors should closely monitor Akumin's financial performance and strategic initiatives to assess its long-term potential. Analyst consensus is Unknown.
What are the main risks for AKU?
Akumin Inc. faces several risks, including changes in reimbursement policies, increased competition from other imaging providers, and the potential for an economic downturn affecting healthcare spending. The company's high debt levels and negative profit margin also pose significant challenges. Additionally, technological obsolescence and integration risks associated with acquisitions could impact Akumin's financial performance and competitive position. Careful monitoring of these factors is crucial for investors.
How does Akumin Inc. navigate regulatory approval processes?
As a provider of diagnostic imaging services, Akumin Inc. is subject to various regulatory requirements and accreditation standards. These include compliance with federal and state regulations governing the operation of imaging equipment, radiation safety, and patient privacy. Akumin works to maintain compliance with these regulations through ongoing training, quality control programs, and regular audits. The company also seeks accreditation from recognized organizations to demonstrate its commitment to quality and safety.
How is Akumin Inc. positioned to benefit from the increasing demand for outpatient diagnostic imaging services?
Akumin Inc. is strategically positioned to benefit from the increasing demand for outpatient diagnostic imaging services due to its extensive network of imaging centers, established relationships with hospitals and health systems, and comprehensive range of services. The company's focus on outpatient services allows it to provide convenient and cost-effective access to high-quality imaging, which is particularly attractive to patients and healthcare providers seeking alternatives to traditional hospital-based imaging. Akumin's ability to expand its network, implement new technologies, and form strategic partnerships will further enhance its competitive advantage in the growing outpatient imaging market.
What are the key factors to evaluate for AKU?
Akumin Inc. (AKU) currently holds an AI score of 53/100, indicating moderate score. Key strength: Extensive network of imaging centers.. Primary risk to monitor: Ongoing: Changes in reimbursement policies affecting revenue and profitability.. This is not financial advice.
How frequently does AKU data refresh on this page?
AKU prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AKU's recent stock price performance?
Recent price movement in Akumin Inc. (AKU) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Extensive network of imaging centers.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for AKU. Financial data based on available information as of 2026-03-16.